Kaczmarek, IngoBeiras-Fernandez, AndresSadoni, SebastianBengel, DominikDeutsch, Marcus-AndreMeiser, BrunoReichart, Bruno2025-10-032005-12Experimental and Clinical Transplantation, Cilt 3, Sayı 2, 2005, ss. 381-3841304-0855https://hdl.handle.net/11727/13674Posttransplant lymphoproliferative disorders are severe complications that arise after solid organ transplantation, which are often related to Epstein-Barr virus. Reports are anecdotal, and a standardized therapy does not exist. We report a case of a 36-year-old man who developed posttransplant lymphoproliferative disorder of the oropharynx 1 year after receiving a heart transplant. A short review of the literature is presented, after which a new therapeutic approach that combines antiviral therapy, monoclonal antibodies, and a sirolimus-based maintenance immunosuppression regimen with reduced target trough levels of tacrolimus is introduced. The patient achieved complete remission and was free from recurrence 18 months after the therapy was initiated.en-USOropharynximmunosuppressionposttransplant lymphoproliferative disordersrituximabantibodiesNovel Treatment with Rituximab of Oropharyngeal Posttransplant Lymphoproliferative Disorder after Heart TransplantationArticle32146-8427